36X Overzicht aandelen Ascentage Pharma Group International, een biotechnologiebedrijf in een klinische fase, ontwikkelt therapieën voor kanker, chronisch hepatitis B-virus (HBV) en ouderdomsziekten op het Chinese vasteland. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Ascentage Pharma Group International Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Ascentage Pharma Group International Historische aandelenkoersen Huidige aandelenkoers HK$5.20 52 Week Hoogtepunt HK$5.75 52 Week Laag HK$1.86 Bèta 1.12 1 maand verandering 10.64% 3 maanden verandering 6.56% 1 Jaar Verandering n/a 3 jaar verandering 88.41% 5 jaar verandering 75.68% Verandering sinds IPO 51.12%
Recent nieuws en updates
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08 Meer updates bekijken
Ascentage Pharma Group International Announces Board and Committee Changes, Effective January 2, 2025 Jan 02 Ascentage Pharma Group International has filed a Follow-on Equity Offering in the amount of $100 million. Dec 28
Ascentage Pharma Releases the Safety and Efficacy Data of the Novel Drug Candidate, Olverembatinib (HQP1351) in Combination the Company's Investigational Novel Bcl-2 Inhibitor, Lisaftoclax Dec 10
Ascentage Pharma Announces New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Nov 28
Ascentage Pharma Appoints Marina S. Bozilenko and Debra Yu as Independent Non-Executive Directors Nov 27
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Oct 08
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Oct 03
Forecast to breakeven in 2026 Aug 28
First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023) Aug 26
New major risk - Revenue and earnings growth Aug 23
Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration Aug 13
Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024 Aug 09
New minor risk - Shareholder dilution Jun 24
Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351) Jun 18
Ascentage Pharma Group International Announces Board and Committee Changes Jun 13
New major risk - Share price stability Jun 09 Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting May 25
Ascentage Pharma Group International, Annual General Meeting, May 10, 2024 Mar 28
Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022) Mar 28
Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting Mar 06
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia Feb 14
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN) Jan 17
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib Dec 15
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR Dec 11
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication Nov 25
China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients Nov 18 Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports
Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc Oct 24
Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia Oct 18
Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE Oct 13
First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022) Sep 24
Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial Aug 22 Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax Aug 08
New minor risk - Share price stability Jul 26
Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All) Jul 06
Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC Jun 06
Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST Jun 01
Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting May 29
Full year 2022 earnings released: CN¥3.35 loss per share (vs CN¥3.07 loss in FY 2021) Mar 23 Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million. Feb 02
Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List Jan 19
Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax Dec 14 Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib
Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License Nov 28
Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies Nov 10
Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B Nov 08
Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb Nov 07 Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting Nov 04
Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting Oct 20 Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential
First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021) Aug 28
Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022 Aug 17
High number of new directors Jul 31
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada Jul 22
Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML Jul 20 Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918
Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress Jun 13
Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL Jun 09
Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC Jun 08 Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development May 27
High number of new directors May 26
Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress May 24
Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022 May 20
Ascentage Pharma Group International Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in Embo Molecular Medicine May 19
Less than half of directors are independent May 02
Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022 Apr 14
Ascentage Pharma Group International, Annual General Meeting, May 19, 2022 Mar 23
Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including A China Study Demonstrating Complete Responses Dec 15
Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Dec 13
Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis Dec 10
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib Dec 01
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Grants Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma Sep 24
Ascentage Pharma Reports the Phase Ib Results of the Dual Bcl-2/Bcl-Xl Inhibitor, Apg-1252 Sep 10
First half 2021 earnings released: CN¥1.53 loss per share (vs CN¥1.53 loss in 1H 2020) Aug 28
Ascentage Pharma Group International Receives Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma Jul 23
Ascentage Pharma Announces IND Clearance by the US FDA for Lisaftoclax (APG-2575) as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors Jun 15 Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs
Non-Executive Director recently sold €2.0m worth of stock Jun 01
Forecast to breakeven in 2023 May 26
Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation May 21
Non-Executive Director has left the company Apr 07
Full year 2020 earnings released: CN¥3.14 loss per share (vs CN¥12.69 loss in FY 2019) Apr 03
Ascentage Pharma Group International to Report Fiscal Year 2020 Results on Mar 31, 2021 Mar 20 Rendement voor aandeelhouders 36X DE Biotechs DE Markt 7D -1.0% 2.5% -0.4% 1Y n/a -10.2% 7.9%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 36X presteerde ten opzichte van de German Biotechs.
Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 36X presteerde ten opzichte van de German markt.
Prijsvolatiliteit Is 36X's price volatile compared to industry and market? 36X volatility 36X Average Weekly Movement 9.5% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stabiele aandelenkoers: De aandelenkoers van 36X is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van 36X is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.
Over het bedrijf Ascentage Pharma Group International, een biotechnologiebedrijf in een klinische fase, ontwikkelt therapieën voor kanker, chronisch hepatitis B-virus (HBV) en leeftijdsgerelateerde ziekten op het Chinese vasteland. De belangrijkste productkandidaat van het bedrijf is HQP1351, een BCR-ABL-remmer die gericht is tegen BCR-ABL1-mutanten, waaronder die met de T315I-mutatie. Het ontwikkelt ook APG-2575, een oraal toegediende Bcl-2 selectieve remmer voor hematologische maligniteiten en solide tumoren; APG-115, een orale kleine molecule remmer van de MDM2-p53 eiwit-eiwit interacties voor de behandeling van solide tumoren en hematologische maligniteiten; en APG-1252, een klein moleculegeneesmiddel om apoptose te herstellen door dubbele inhibitie van de Bcl-2- en Bcl-xL-eiwitten voor de behandeling van kleincellige longkanker, niet-kleincellige longkanker, neuro-endocriene tumor en non-Hodgkin-lymfoom.
Meer tonen Ascentage Pharma Group International Samenvatting Hoe verhouden de winst en inkomsten van Ascentage Pharma Group International zich tot de beurswaarde? 36X fundamentele statistieken Marktkapitalisatie €1.69b Inkomsten(TTM ) -€47.76m Inkomsten(TTM ) €119.72m
14.1x P/S-verhouding
-35.4x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 36X resultatenrekening (TTM ) Inkomsten CN¥903.03m Kosten van inkomsten CN¥27.45m Brutowinst CN¥875.58m Overige uitgaven CN¥1.24b Inkomsten -CN¥360.28m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -1.16 Brutomarge 96.96% Nettowinstmarge -39.90% Schuld/Eigen Vermogen Verhouding 216.3%
Hoe presteerde 36X op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/05 08:38 Aandelenkoers aan het einde van de dag 2025/01/03 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Ascentage Pharma Group International wordt gevolgd door 13 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Yang Huang BofA Global Research Jin Zhang China International Capital Corporation Limited Wangbin Zhou China International Capital Corporation Limited
Toon 10 meer analisten 
